25 June 2010
A comparative study of the antiemetic efficacy of dexamethasone, ondansetron, and metoclopramide in patients undergoing gynecological surgery
Tugsan Egemen BilginABDEF, Handan BirbicerABDEF, Zeliha OzerADE, Nurcan DorukBDF, Ekrem TokABC, Ugur OralGMed Sci Monit 2010; 16(7): CR336-341 :: ID: 880929
Abstract
Background: Postoperative nausea and vomiting (PONV) are some of the most-common and undesirable adverse effects after surgery performed under general anesthesia. We investigated the prophylactic value of dexamethasone as an alternate to ondansetron or metoclopramide to prevent PONV after gynecologic surgery.
Material/Methods: One hundred sixty ASA I-II patients scheduled for elective gynecologic surgery were enrolled. Before induction of anesthesia, patients were randomly allocated to receive intravenously dexamethasone (8 mg) in group D, ondansetron (4 mg) in group O, metoclopramide (10 mg) in group M, and saline (2 mL) in group P. Total incidence of nausea and vomiting, rescue antiemetic requirement, pain scores, and any adverse effects were recorded at 3 observational periods (0–2 hours, 2–12 hours, and 12–24 hours).
Results: Total rates of PON, POV, and PONV were significantly higher in group P at 0–2 hours and 2–12 hours compared with group D, O, and M (P<.05). There was no difference in PON, POV, and PONV among D, O, and M groups. None of the groups differed in PONV in the subsequent 12–24 hours. Number of patients requiring rescue antiemetic was significantly higher in group P than the other groups at 0–2 hours (10%, 10%, 15%, and 45% in group D, O, M, and P) (P<.05).
Conclusions: Prophylactic IV dexamethasone 8 mg significantly reduces the incidence of PONV in gynecologic surgery. At this dosage, dexamethasone is as effective as ondansetron 4 mg and metoclopramide 10 mg, and is more-effective than placebo.
Keywords: Postoperative Nausea and Vomiting - etiology, Ondansetron - therapeutic use, Hysterectomy, Metoclopramide - therapeutic use, Gynecologic Surgical Procedures - adverse effects, Dexamethasone - therapeutic use, Antiemetics - therapeutic use, young adult
Editorial
01 January 2025 : Editorial
Editorial: The Human Cell Atlas. What Is It and Where Could It Take Us?DOI: 10.12659/MSM.947707
Med Sci Monit 2025; 31:e947707
In Press
Clinical Research
Factors Affecting Medication Adherence in Middle-Aged and Elderly Patients in China: A Cross-Sectional StudyMed Sci Monit In Press; DOI: 10.12659/MSM.945805
Review article
Characteristics and Associated Risk Factors of Broad Ligament Hernia: A Systematic ReviewMed Sci Monit In Press; DOI: 10.12659/MSM.946710
Clinical Research
Cost-Effective Day Surgery for Arteriovenous Fistula Stenosis: A Viable Model for Hemodialysis PatientsMed Sci Monit In Press; DOI: 10.12659/MSM.946128
Clinical Research
Impact of Periodontal Treatment on Early Rheumatoid Arthritis and the Role of Porphyromonas gingivalis Anti...Med Sci Monit In Press; DOI: 10.12659/MSM.947146
Most Viewed Current Articles
17 Jan 2024 : Review article 6,963,777
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research 700,314
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Mar 2024 : Editorial 23,719
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and ...DOI :10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
28 Jan 2024 : Review article 18,460
A Review of IgA Vasculitis (Henoch-Schönlein Purpura) Past, Present, and FutureDOI :10.12659/MSM.943912
Med Sci Monit 2024; 30:e943912